SRRK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Scholar Rock Holding Corp (SRRK) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong analyst support with increasing price targets, a bullish technical setup, and improving financial metrics. While there are no immediate trading signals or recent news catalysts, the long-term outlook and reduced manufacturing risks make it a solid investment opportunity.
The technical indicators are bullish. The MACD histogram is above 0 and positively contracting, the RSI is neutral at 51.078, and the moving averages (SMA_5 > SMA_20 > SMA_200) suggest an upward trend. The stock is trading above its pivot point of 46.67, with resistance levels at 49.092 and 50.588, indicating potential for further upside.
Analysts have consistently raised price targets, with the most recent target at $58, reflecting confidence in apitegromab's launch trajectory.
Manufacturing issues are being resolved, reducing uncertainty and de-risking the early launch.
Improving financial metrics, including a 58.53% YoY improvement in net income and a 36.36% YoY increase in EPS.
The stock shows a 50% chance of declining in the short term (-1.61% in the next day, -5.78% in the next week, and -3.46% in the next month).
No recent news or congress trading data to provide additional sentiment or validation.
In Q3 2025, the company showed significant improvement in financial metrics despite no revenue. Net income improved by 58.53% YoY to -$102.22M, and EPS increased by 36.36% YoY to -0.9. Gross margin remains at 0%.
Analysts are overwhelmingly positive on SRRK, with multiple Buy ratings and price targets ranging from $42 to $60. Recent updates highlight reduced manufacturing risks and confidence in apitegromab's market potential.
